A Study to Assess the Bioequivalence of Ustekinumab by Two Different Injection Devices in Healthy Participants
Status:
Recruiting
Trial end date:
2022-01-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the pharmacokinetic (PK) and bioequivalence (BE) of
ustekinumab administered by a single subcutaneous (SC) injection with Device 1 or Device 2 in
healthy participants.